<DOC>
	<DOCNO>NCT01606007</DOCNO>
	<brief_summary>The purpose study learn combination BMS-477118 ( Saxagliptin ) BMS -512148 ( Dapagliflozin ) add Metformin improve ( decrease ) Glycosylated Hemoglobin ( Hemoglobin A1c ) patient type 2 diabetes 24 week treatment . The safety treatment also study .</brief_summary>
	<brief_title>Safety Efficacy Combination Saxagliptin &amp; Dapagliflozin Added Metformin Treat Subjects With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Saxagliptin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Subjects Type 2 diabetes mellitus ( T2DM ) HbA1c ≥ 8.0 % ≤ 12.0 % Stable metformin therapy dose ≥ 1500mg least 8 week prior screen Body mass index ( BMI ) ≤ 45.0kg/m2 Estimated glomerular filtration rate ( eGFR ) &lt; 60mL/min/1,73m2 Serum Creatinine ( Scr ) ≥ 1.5 mg/dL male ≥ 1.4 mg/dL female Uncontrolled hypertension Systolic Blood Pressure ( SBP ) ≥ 160mmHg and/or Diastolic Blood Pressure ( DBP ) ≥ 100mmHg Hepatic disease Cardiovascular disease within 3 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>